

# Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

## Flt3 ligand antibody [EP1140Y]

RRID:AB\_2104974

Type: Antibody

---

### Proper Citation

Abcam Cat# ab52648, RRID:AB\_2104974

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2104974](http://antibodyregistry.org/AB_2104974)

**Proper Citation:** Abcam Cat# ab52648, RRID:AB\_2104974

**Target Antigen:** Human Flt3 ligand

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** validation status unknown, seller recommendations provided in 2012: Flow Cytometry; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Western Blot; Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-P, Western Blot

**Antibody Name:** Flt3 ligand antibody [EP1140Y]

**Description:** This monoclonal targets Human Flt3 ligand

**Target Organism:** human

**Clone ID:** Clone EP1140Y

**Antibody ID:** AB\_2104974

**Vendor:** Abcam

**Catalog Number:** ab52648

**Record Creation Time:** 20250819T233604+0000

**Record Last Update:** 20250820T055100+0000

---

### Ratings and Alerts

No rating or validation information has been found for Flt3 ligand antibody [EP1140Y].

No alerts have been found for Flt3 ligand antibody [EP1140Y].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Zhang Z, et al. (2022) Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. *Frontiers in oncology*, 12, 974573.

Joshi SK, et al. (2021) The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. *Cancer cell*, 39(7), 999.